Ameco Research Analyst suggest that the global market for Sodium Citrate Blood Specimen Collection Tubes is likely to grow with a CAGR of 7.6% throughout the predicted years
Because of a spike in demand throughout the COVID-19 public health emergency and recent vendor supply issues, the Food and Drug Administration (FDA) is aware that the United States is experiencing severe disruptions in the availability of blood specimen collection (blood draw) tubes. The FDA revised the device shortage list on January 19, 2022, to add all blood specimen collecting tubes (product codes GIM and JKA). Only sodium citrate (light blue top) tubes were previously added to the device shortage list by the FDA on June 10, 2021. The FDA advises laboratory directors, healthcare providers, phlebotomists, and other healthcare professionals to investigate blood specimen collection tube conservation measures to reduce blood collection tube used while maintaining high-quality and safe patient care.
Request for a sample of this premium research report @ https://www.amecoresearch.com/sample/276614
During the COVID-19 public health emergency, the FDA added these collectors (product codes JKA and GIM) to section 50 6J of the Federal Food, Drug, and Cosmetic Act apparatus shortage list on June 10, 2021. Furthermore, on July 22, 2021, the FDA granted Becton, Dickinson a EUA for new product "BD Vacutainer Plus Citrate Plasma Collection Tubes" (Produced in UK site). These are blood sample collection tubes utilized to collect, store, and transport blood tests for coagulation testing. The device approved under this EUA is for use in CLIA certified labs non-waived coagulation tests to assist in the classification and healing of coagulopathy in people, counting patients with COVID-19. The FDA is continuing to supervise the situation to make sure that coagulation testing is available to people who require it for medical reasons. If significant new information becomes available, the FDA will notify the public.
The FDA can recognize and better understand the threats linked with medical devices if adverse occurrences are reported promptly. Furthermore, the FDA wants to hear from healthcare providers and facilities that are having trouble procuring devices, in addition to other shareholders who may be capable to help minimize possible shortages.
The College of American Pathologists (CAP) reported in June 2021 that sodium citrate blood specimen collecting tubes were in short supply by 3.2 percent (light blue top tubes). Several recalls, as well as unusual demand for citrate products due to a surge in COVID-19 infection rates, have resulted in a shortage of these tubes. The FDA advises health care providers, laboratory directors, phlebotomists, and other professionals to investigate blood specimen collection tube conservation measures to reduce blood collection tube use while maintaining high-quality and safe patient care.
Manufacturers built bright blue top tubes with varied color lids for excellent reasons, according to the IBMS research. Various hues symbolise different ingredients for a reason. These different hues signify different additives found within the tubes, and they are labelled according to international regulations (ISO 6710:2017).
The global sodium citrate blood specimen collection tube market is driven by the rising occurrence of blood clotting diseases (Venous Thromboembolism). According to a research published by the American Society of Hematology, the coagulopathies and thrombotic consequences associated with COVID-19 infection are to blame for the spike in coagulation testing demand. This happened in the midst of a worldwide scarcity of sodium citrate, a vital component in the light blue top tubes.
Global Sodium Citrate Blood Specimen Collection Tubes Market Scope
End-user and geography are the two components that make up the sodium citrate blood specimen collection tubes market. Based on end-user, the market is divided into diagnostic centers, hospitals, medical clinics, and others. Among them, hospitals are likely to achieve a substantial market share in 2020 and are likely to retain their dominant position in the coming years. The high growth in the segment is ascribed to the growing number of blood tests in the hospitals, the increasing prevalence of deep vein thrombosis (DVT), and the presence of advanced healthcare facilities in the hospitals.
North America, Latin America, Asia-Pacific, Europe, and the Middle East & Africa (MEA) are the regional categorization of the worldwide sodium citrate blood specimen collection tubes market. Based on regions, the Asia-Pacific region accumulated the largest market share in 2020 and is witnessed to do the same for the predicted years. The growing number of blood tests due to the increasing number of infectious diseases, growing incidence of blood clot disorders, rising elderly population, etc is all driving up the demand for the Asia-Pacific sodium citrate blood specimen collection tubes industry.
Some of the prominent companies covered in the research report are AdvaCare Pharma, Becton Dickinson (BD), Laboratory Corporation of America®, CML Biotech (P) Ltd., Greiner Bio-One International GmbH, Neu Micromed International Pvt. Ltd., and FL MEDICAL s.r.l.
To receive personalized service, please share your research needs here@ https://www.amecoresearch.com/enquiry-before-buy/276614
Buy this premium research report - https://www.amecoresearch.com/buy/276614
USA: +1 347 474 3864
India: +91 8983225533